Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
Financials
Financial year 2024
PHARMALAW from Anderlecht, company number BE0679616642, closed financial year 2024 with a result of € -10,079 after tax. For that financial year PHARMALAW recorded a gross margin of € 448,782 and equity of € 1.2 million. Compared with financial year 2023, the result moved from € -103,617 to € -10,079. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2025.
€ 1.2 million
▼ 1% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -10,079
▲ 90 % less loss than in 2023
Profit after tax over the fiscal year.
€ 112,748
▼ 7% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 1.2 million.
People and assets in 2024
2.2
▼ 0.2 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 110,528
▼ 7% vs 2023
€ 50,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 8,432
▲ 34% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
€ 1.4 million
▼ 8% vs 2023
€ 128,772 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 113,437
▼ 28% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 62,525
▲ 11% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 170,093 | € 227,131 | € 287,297 | € 448,782 | ▲ 56% |
| Profit after taxes | € 107,041 | € 137,178 | € -103,617 | € -10,079 | ▲ € 93,538 |
| Equity | € 1,163,063 | € 1,281,491 | € 1,177,874 | € 1,167,795 | ▼ 1% |
| Total debts | € 936,863 | € 1,582,221 | € 1,903,564 | € 1,737,160 | ▼ 9% |
| Cash | € 95,140 | € 109,953 | € 121,338 | € 112,748 | ▼ 7% |
| Land & buildings | - | € 590,701 | € 686,983 | € 917,039 | ▲ 33% |
| Retained profit | € 1,156,813 | € 1,275,241 | € 1,171,624 | € 1,161,545 | ▼ 1% |
| Dividend | € 0 | € 18,750 | € 0 | € 0 | |
| Bank debt | € 744,033 | € 1,327,317 | € 1,546,892 | € 1,423,909 | ▼ 8% |
| Balance sheet total | € 2,099,926 | € 2,863,713 | € 3,081,438 | € 2,904,955 | ▼ 6% |
| Employees (FTE) | - | - | 2.4 | 2.2 | ▼ 0.2 |
Key figures of PHARMALAW, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to PHARMALAW?
What happened at PHARMALAW in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 10,079. filed late Source: NBB ↗
- New establishment in Rebecq. KBO
- Start of the company according to the CBE. KBO
In short
From € 107,041 profit in 2021 to € 10,079 loss in 2024.
Paid € 118,303 in corporate taxes since 2021.
Best year ever: 2022, with € 137,178 profit.
On average € 204,000 of value added per employee in 2024.
A new publication or filing at PHARMALAW? We notify you, reason included.
Follow PHARMALAWDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMALAW is ALI EMDADI MILAD. ALI EMDADI MILAD is also behind PHARMATRUST, PHARMACIE MONTENEGRO, PHARMA DISCOUNT and Pharmacie Armée Britannique.
Directors
According to the 2024 annual accounts
ALI EMDADI MILAD
Director
Also active at: PHARMATRUST, PHARMACIE MONTENEGRO, PHARMA DISCOUNT, Pharmacie Armée Britannique
Establishments
Establishment units
Physical locations of this company
Agavendreef 9
1070 Anderlecht
Rue du Faubourg 1
1430 Rebecq
Active since 7 August 2017
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0679.616.642
- VAT number
- BE 0679.616.642
- Registered office
- Agavendreef 9, 1070 Anderlecht
- Names & denominations
- PHARMALAW
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 August 2017
- Peppol
- Active · Active since 12 Sept 2025
- Contact
- [email protected] +32484431889
- Activities · NACE
Detailhandel in farmaceutische producten